NEW YORK – Additional analysis from the ADAURA trial presented during the European Society for Medical Oncology's Virtual Congress on Saturday, particularly data showing that adjuvant osimertinib (AstraZeneca's Tagrisso) may curb central nervous system (CNS) disease recurrence, is further bolstering the case for the drug.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.